Literature DB >> 3619198

Mechanical properties and structure of isolated pulmonary arteries remodeled by chronic hyperoxia.

J T Coflesky, R C Jones, L M Reid, J N Evans.   

Abstract

Normobaric hyperoxia is known to cause pulmonary hypertension with major restructuring of the walls of large and small pulmonary arteries. This study reports the effects of 21 days of exposure to 87% oxygen on the resting and active mechanical properties and structure of pulmonary arterial segments. Segments from the hilar region, extrapulmonary and proximal preacinar, and selected distal preacinar regions were studied. Resting and active (KCl-induced) tension:circumference curves were determined for each vessel. Morphometric measures were made of vessels fixed at a standard circumference using computerized planimetry. The areas of the media and adventitia as well as vessel wall thickness were increased in hyperoxic vessels. The walls of segments from the hypertensive rats demonstrated an increased stiffness based upon analysis of vessel resting tension:circumference relationships while the tangent modulus (a measure of stiffness normalized to tissue dimensions) was unchanged. Paradoxically, despite medial hypertrophy in the pulmonary vessels remodeled by hyperoxia, active tension was reduced. This study reveals that the resulting hypertensive state is not readily explained by an inherent increase in the maximal contractile capabilities of the remodeled vessel. Rather, obliteration of vessels in combination with increased resting stiffness appear to be the basis for pulmonary hypertension induced in hyperoxia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3619198     DOI: 10.1164/ajrccm/136.2.388

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  7 in total

Review 1.  Airway hyperresponsiveness in asthma: not just a matter of airway inflammation.

Authors:  V Brusasco; E Crimi; R Pellegrino
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

2.  Injury and remodeling of pulmonary veins by high oxygen. A morphometric study.

Authors:  L M Hu; R Jones
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

Review 3.  Structure and composition of pulmonary arteries, capillaries, and veins.

Authors:  Mary I Townsley
Journal:  Compr Physiol       Date:  2012-01       Impact factor: 9.090

4.  Regional heterogeneity of elastin and collagen gene expression in intralobar arteries in response to hypoxic pulmonary hypertension as demonstrated by in situ hybridization.

Authors:  I W Prosser; K R Stenmark; M Suthar; E C Crouch; R P Mecham; W C Parks
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

5.  Proliferative changes in the pulmonary arterial wall during short-term hyperoxic injury to the lung.

Authors:  J T Coflesky; K B Adler; J Woodcock-Mitchell; J Mitchell; J N Evans
Journal:  Am J Pathol       Date:  1988-09       Impact factor: 4.307

6.  Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertension.

Authors:  Natasha M Rogers; Mingyi Yao; John Sembrat; M Patricia George; Heather Knupp; Mark Ross; Maryam Sharifi-Sanjani; Jadranka Milosevic; Claudette St Croix; Revathi Rajkumar; Maria G Frid; Kendall S Hunter; Luciano Mazzaro; Enrico M Novelli; Kurt R Stenmark; Mark T Gladwin; Ferhaan Ahmad; Hunter C Champion; Jeffrey S Isenberg
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

7.  NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling.

Authors:  Scott A Barman; Feng Chen; Yunchao Su; Christiana Dimitropoulou; Yusi Wang; John D Catravas; Weihong Han; Laszlo Orfi; Csaba Szantai-Kis; Gyorgy Keri; Istvan Szabadkai; Nektarios Barabutis; Olga Rafikova; Ruslan Rafikov; Stephen M Black; Danny Jonigk; Athanassios Giannis; Reto Asmis; David W Stepp; Ganesan Ramesh; David J R Fulton
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-06-19       Impact factor: 8.311

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.